Amarin Corp. plc (NASDAQ:AMRN): 09:53 EDT Amarin jumps 9%, or 65c, to $7.80.
The shares closed at $8.02, up $0.87, or 12.17%, on the day. Its market capitalization is $1.09 billion.
LHC Group, Inc. (NASDAQ:LHCG): PE firm TPG Capital is weighing a bid for LHC Group (NASDAQ:LHCG), which has previously announced it is reviewing its strategic alternatives, sources told Reuters. TPG declined to comment and an LHC spokesman did not respond to a request for comment, the report noted.
The shares closed at $19.65, up $1.29, or 7.03%, on the day. Its market capitalization is $359.57 million.
Sunesis Pharmaceuticals (NASDAQ:SNSS): VALOR interim analysis: Sunesis expects the planned interim analysis of the VALOR trial by the DSMB to occur in the third quarter of 2012. As previously announced, the DSMB will meet to examine pre-specified efficacy and safety data sets and decide whether to 1) stop the trial early for efficacy or for futility; 2) continue the study to its planned unblinding, expected in mid-2013; or 3) recommend a one-time “adaptive” sample size increase with unblinding expected in early 2014.
The shares closed at $2.46, down $0.17, or 6.46%, on the day. Its market capitalization is $114.92 million.
Johnson & Johnson (NYSE:JNJ): Forest Laboratories (NYSE:FRX) and Forest Laboratories Holdings announced that Forest and Janssen Pharmaceutica NV (NYSE:JNJ) have jointly filed a lawsuit in the U.S. District Court for the District of Delaware against several companies for infringement of U.S. Patent No. 6,545,040, relating to Forest’s BYSTOLIC product. Forest licenses the 040 patent from Janssen. The 040 patent expires in December 2021, including patent term extension. The defendants named in the lawsuit include Amerigen Pharmaceuticals, Inc., Glenmark Generics, Inc., Hetero USA Inc., Torrent Pharmaceuticals Ltd., Watson Laboratories (NYSE:WPI) and related companies and subsidiaries thereof. Janssen and Forest also filed a lawsuit in the U.S. District Court for the Northern District of Illinois against Alkem Laboratories Limited and Indchemie Health Specialties Pvt. Ltd for infringement of the 040 patent.
The shares closed at $65.08, down $0.25, or 0.38%, on the day. Its market capitalization is $178.65 billion.
Merck & Co., Inc. (NYSE:MRK): The filings include BRIDION, Odanacatib, Suvorexant, TREDAPTIVE, and V503. Comments taken from slides for Barclays Healthcare Conference.
The shares closed at $38.22, down $0.06, or 0.16%, on the day. Its market capitalization is $116.34 billion.
Teva Pharmaceutical (NASDAQ:TEVA): Teva Pharmaceutical Industries (NASDAQ:TEVA) announced that it has commenced commercial launch of Escitalopram Oxalate Tablets, the company’s generic version of Forest Laboratories’ (NYSE:FRX) depression and generalized anxiety disorder treatment, Lexapro Tablets. As the first company to file an Abbreviated New Drug Application containing a paragraph IV certification for this product, Teva has been awarded a 180-day period of marketing exclusivity.
The shares closed at $43.80, down $0.64, or 1.44%, on the day. Its market capitalization is $41.26 billion.
Want news like this in real-time so you can get an edge? Click here for Wall St. Cheat Sheet Pro.
To contact the reporter on this story: Stella Mariz at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com